C07K2317/41 - page 6 - CPC Classification Index

#1501

20140112927

2014-04-24

Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration

#1502

20140112914

2014-04-24

Cytotoxicity-inducing therapeutic agent

#1503

20140112910

2014-04-24

Modified glycoproteins

#1504

20140105922

2014-04-17

Variant target binding agents and uses thereof

#1505

20140086916

2014-03-27

Method for preparing Fc containing polypeptides having improved properties

#1506

20140086906

2014-03-27

Optimized antibodies that target CD19

#1507

20140081004

2014-03-20

Glycosylated specificity exchangers

#1508

20140079702

2014-03-20

Method of improving patient survivability and quality of life by anti-IL-6 antibody administration

#1509

20140073005

2014-03-13

Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function

#1510

20140072528

2014-03-13

Combination IL-2 immunoconjugate therapy

#1511

20140065710

2014-03-06

Methods to control protein heterogeneity

#1512

20140065150

2014-03-06

Methods and systems for treating eclampsia or pre-eclampsia

#1513

20140065063

2014-03-06

Therapeutic use of anti-CS1 antibodies

#1514

20140057319

2014-02-27

Methods and vectors for generating asialylated immunoglobulins

#1515

20140051836

2014-02-20

Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use

#1516

20140051835

2014-02-20

Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells

#1517

20140044714

2014-02-13

Human monoclonal antibodies specific for glypican-3 and use thereof

#1518

20140037648

2014-02-06

Antibodies that neutralize RSV, MPV and PVM and uses thereof

#1519

20140017243

2014-01-16

Use of ADCC-optimized antibodies for treating weak patients

#1520

20140005368

2014-01-02

Low fucose cell lines and uses thereof

#1521

20130344088

2013-12-26

Anti-BAFFR antibody formulation

#1522

20130336975

2013-12-19

Anti-NGF compositions and use thereof

#1523

20130330770

2013-12-12

Methods for modulating mannose content of recombinant proteins

#1524

20130323238

2013-12-05

Antagonists of IL-6 to raise albumin and/or lower CRIP

#1525

20130288302

2013-10-31

Humanized anti-beta7 antagonists and uses therefor

#1526

20130280280

2013-10-24

B cell maturation antigen (BCMA) binding proteins

#1527

20130280246

2013-10-24

Humanized antibodies with anti-tumor activity

#1528

20130251707

2013-09-26

Anti-huTNFR1 antibody and methods of use thereof for treatment

#1529

20130236535

2013-09-12

Antibodies

#1530

20130230530

2013-09-05

Human antibodies that bind CD22 and uses thereof

#1531

20130230513

2013-09-05

Assay method for Alzheimer's disease

#1532

20130224201

2013-08-29

Antibodies to IL-6 to inhibit or treat inflammation

#1533

20130224190

2013-08-29

Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile

#1534

20130209458

2013-08-15

Fab-glycosylated antibodies

#1535

20130209457

2013-08-15

Optimized Fc variants

#1536

20130209455

2013-08-15

Humanized anti-CDCP1 antibodies

#1537

20130196379

2013-08-01

Antibodies

#1538

20130196378

2013-08-01

Human monoclonal antibody

#1539

20130189736

2013-07-25

Antibody composition-producing cell

#1540

20130189250

2013-07-25

Human tissue factor antibody and uses thereof

#1541

20130183306

2013-07-18

Anti-CD19 antibody having ADCC function with improved glycosylation profile

#1542

20130183264

2013-07-18

Antagonists of IL-6 to raise albumin and/or lower CRP

#1543

20130164786

2013-06-27

Fucosylation-deficient cells

#1544

20130142783

2013-06-06

Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease

#1545

20130137857

2013-05-30

Transglycosylation activity of glycosynthase mutants of an endo-beta-N-acetylglucosaminidase (endo-D) from streptococcus pneumoniae

#1546

20130136735

2013-05-30

Humanized antibodies to iNKT

#1547

20130129784

2013-05-23

Methods of inhibition of protein fucosylation in vivo using fucose analogs

#1548

20130115657

2013-05-09

Humanized anti-CD19 antibodies

#1549

20130109593

2013-05-02

Expression of monoclonal antibodies in ciliate host cells

#1550

20130101598

2013-04-25

Antagonists of IL-6 to prevent or treat thrombosis

#1551

20130096283

2013-04-18

Method of supplementing culture media to prevent undesirable amino acid substitutions

#1552

20130078251

2013-03-28

Anti-MCSP antibodies

#1553

20130071390

2013-03-21

Method for preparing antibodies having improved properties

#1554

20130058917

2013-03-07

ANTIBODY COMPOSITION OBTAINED BY FRACTIONATION OF PLASMA IMMUNOGLOBULINS AFFINITY CHROMATOGRAPHY ON A SAMBUCUS NIGRA AFFINITY COLUMN

#1555

20130053550

2013-02-28

YEAST STRAINS PRODUCING MAMMALIAN-LIKE COMPLEX N-GLYCANS

#1556

20130041131

2013-02-14

Glycosylated specificity exchangers

#1557

20130039913

2013-02-14

Heterodimeric antibody Fc-containing proteins and methods for production thereof

#1558

20130039907

2013-02-14

Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow

#1559

20130034566

2013-02-07

Anti-CDH3 antibodies and uses thereof

#1560

20130028906

2013-01-31

Human antibodies that bind mesothelin, and uses thereof

#1561

20130028905

2013-01-31

Human antibodies that bind mesothelin, and uses thereof

#1562

20130028904

2013-01-31

Human antibodies that bind mesothelin, and uses thereof

#1563

20130028860

2013-01-31

Anti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity

#1564

20130022618

2013-01-24

Human cytomegalovirus neutralizing antibodies and use thereof

#1565

20130017575

2013-01-17

Nucleic acids encoding anti-IL-6 antibodies of defined epitopic specificity

#1566

20130011412

2013-01-10

Antibodies to lymphotoxin-alpha

#1567

20130011394

2013-01-10

COMPLEXES COMPRISING MHC CLASS I FUSION POLYPEPTIDES AND ANTIGEN-SPECIFIC ANTIBODIES AND METHODS OF USE

#1568

20120328626

2012-12-27

Method for increasing N-glycosylation site occupancy on therapeutic glycoproteins produced in

#1569

20120322101

2012-12-20

Production of glycoproteins with reduced O-glycosylation

#1570

20120315280

2012-12-13

Methods of treating mucositis using anti-TNF antibodies

#1571

20120315268

2012-12-13

COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE

#1572

20120309941

2012-12-06

IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS

#1573

20120309940

2012-12-06

GLYCOSYLATED REPEAT-MOTIF-MOLECULE CONJUGATES

#1574

20120302739

2012-11-29

BIOLOGICAL PRODUCTS

#1575

20120301894

2012-11-29

LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS

#1576

20120301429

2012-11-29

DAC HYP COMPOSITIONS AND METHODS

#1577

20120295273

2012-11-22

N-acetylhexosamine-containing N-glycans in glycoprotein products

#1578

20120294852

2012-11-22

ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRP

#1579

20120288504

2012-11-15

Antagonists of IL-6 to prevent or treat thrombosis

#1580

20120276631

2012-11-01

Methods for controlling the galactosylation profile of recombinantly-expressed proteins

#1581

20120276125

2012-11-01

Immunoconjugates

#1582

20120276103

2012-11-01

VHH for application in tissue repair, organ regeneration, organ replacement and tissue engineering

#1583

20120276099

2012-11-01

Monospecific polypeptide reagents

#1584

20120276092

2012-11-01

Antibody Glycosylation Variants

#1585

20120276086

2012-11-01

MONOCLONAL ANTIBODIES AGAINST CD30 LACKING IN FUCOSYL AND XYLOSYL RESIDUES

#1586

20120269805

2012-10-25

Antibodies directed against amyloid-beta peptide and methods using same

#1587

20120266260

2012-10-18

DIAGNOSING AND TREATING IGA NEPHROPATHY

#1588

20120263713

2012-10-18

Combination therapy of an afucosylated CD20 antibody with fludarabine and/or mitoxantrone

#1589

20120263711

2012-10-18

Engineering Fc Antibody Regions to Confer Effector Function

#1590

20120259095

2012-10-11

Monoclonal antibodies with enhanced ADCC function

#1591

20120258496

2012-10-11

PRODUCTION OF LOW FUCOSE ANTIBODIES IN H4-II-E RAT CELLS

#1592

20120258096

2012-10-11

Anti-D monoclonal antibodies

#1593

20120258039

2012-10-11

Treatment of tumors using specific anti-L1 antibody

#1594

20120253016

2012-10-04

ANTIBODY MOLECULES THAT BIND TO IL-6 RECEPTOR

#1595

20120251533

2012-10-04

Monoclonal antibodies against CD30 lacking in fucosyl residues

#1596

20120251529

2012-10-04

Anti-CEA antibodies

#1597

20120244163

2012-09-27

BISPECIFIC BINDING AGENTS TARGETING IGF-1R AND ERBB3 SIGNALLING AND USES THEREOF

#1598

20120244152

2012-09-27

Antagonist antibodies and their fab fragments against GPVI and uses thereof

#1599

20120244151

2012-09-27

Treatment of cancer involving mutated KRAS or BRAF genes

#1600

20120244142

2012-09-27

ANTIBODY CAPABLE OF RECOGNIZING HLA CLASS I

#1601

20120237973

2012-09-20

Production of glycoproteins with reduced O-glycosylation

#1602

20120237528

2012-09-20

Human tissue factor antibody and uses thereof

#1603

20120237521

2012-09-20

Compositions and methods for increasing muscle growth

#1604

20120237506

2012-09-20

Dual FC antigen binding proteins

#1605

20120231005

2012-09-13

AX1 PCSK9 antagonists

#1606

20120230987

2012-09-13

Methods for treating conditions associated with c-fms

#1607

20120230980

2012-09-13

Optimized Fc variants and methods for their generation

#1608

20120226024

2012-09-06

Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof

#1609

20120219551

2012-08-30

Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use

#1610

20120219549

2012-08-30

Combination therapy of a type II anti-CD20 antibody with a proteasome inhibitor

#1611

20120214975

2012-08-23

Process for producing molecules containing specialized glycan structures

#1612

20120208984

2012-08-16

Humanized anti-beta7 antagonists and uses therefor

#1613

20120208238

2012-08-16

Engineered immunoglobulin FC polypeptides

#1614

20120196310

2012-08-02

A-FUCOSYLATION DETECTION IN ANTIBODIES

#1615

20120195885

2012-08-02

COMPOSITIONS CONTAINING GLYCOSYLATED ANTIBODIES AND USES THEREOF

#1616

20120190070

2012-07-26

Sp35 antibodies and uses thereof

#1617

20120178127

2012-07-12

Nucleic acid encoding apoptotic anti-IgE antibodies

#1618

20120178106

2012-07-12

Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof

#1619

20120177635

2012-07-12

Methods of using apoptotic anti-IGE antibodies

#1620

20120171722

2012-07-05

Personalized production of biologics and method for reprogramming somatic cells

#1621

20120171198

2012-07-05

Use of IgGimmunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route

#1622

20120164161

2012-06-28

Antibodies which bind to the human CC chemokine receptor 4 and uses thereof

#1623

20120164137

2012-06-28

ANTI-FOLATE RECEPTOR ALPHA ANTIBODY GLYCOFORMS

#1624

20120164067

2012-06-28

Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75

#1625

20120149881

2012-06-14

Apoptotic anti-IgE antibodies

#1626

20120149873

2012-06-14

Method for purifying albumin

#1627

20120149085

2012-06-14

Fusion proteins containing recombinant cytotoxic RNAses

#1628

20120148576

2012-06-14

HUMANIZED ANTI-CD 19 ANTIBODY FORMULATIONS

#1629

20120148490

2012-06-14

Anti-NGF compositions and use thereof

#1630

20120144512

2012-06-07

TRANSGENIC ANIMALS EXPRESSING HUMAN IGE-M1'

#1631

20120142900

2012-06-07

ANTIBODIES TO IL-6 AND USE THEREOF

#1632

20120141486

2012-06-07

Human monoclonal antibody

#1633

20120141485

2012-06-07

Methods of preventing or treating pain using anti-NGF antibodies

#1634

20120141484

2012-06-07

Methods of preventing inflammation and treating pain using anti-NGF compositions

#1635

20120135461

2012-05-31

PRODUCTION OF GLYCOPROTEINS WITH REDUCED O-GLYCOSYLATION COMPRISING THE USE OF AN ALPHA-1,2-MANNOSIDASE

#1636

20120134990

2012-05-31

COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES

#1637

20120134988

2012-05-31

POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS

#1638

20120134925

2012-05-31

Application and uses of PRG4 and therapeutic modulation thereof

#1639

20120129237

2012-05-24

Polynucleotides encoding novel PCSK9 variants

#1640

20120129216

2012-05-24

Enzymatic antibody processing

#1641

20120128723

2012-05-24

Cancer specific antibody and cell surface proteins

#1642

20120128692

2012-05-24

Human cytomegalovirus neutralizing antibodies and use thereof

#1643

20120128691

2012-05-24

Human cytomegalovirus neutralizing antibodies and use thereof

#1644

20120128664

2012-05-24

Glycosylated antibodies

#1645

20120128591

2012-05-24

Anti-FAP antibodies and methods of use

#1646

20120122206

2012-05-17

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

#1647

20120121578

2012-05-17

METHODS OF USING IMMUNOGLOBULIN AGGREGATES

#1648

20120100575

2012-04-26

Nucleic acids encoding antibodies having altered effector function and methods for making the same

#1649

20120100140

2012-04-26

STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHODS OF USE

#1650

20120093826

2012-04-19

Fully human antibodies specific to CADM1

#1651

20120087861

2012-04-12

Human anti-tau antibodies

#1652

20120082664

2012-04-05

OPTIMIZED ANTIBODIES THAT TARGET CD19

#1653

20120070440

2012-03-22

Therapeutic use of anti-CS1 antibodies

#1654

20120064083

2012-03-15

Therapeutic use of anti-CS1 antibodies

#1655

20120064081

2012-03-15

Anti-KIR3D antibodies

#1656

20120064069

2012-03-15

Therapeutic use of anti-CS1 antibodies

#1657

20120064068

2012-03-15

Therapeutic use of anti-CS1 antibodies

#1658

20120064067

2012-03-15

Therapeutic use of anti-CS1 antibodies

#1659

20120059155

2012-03-08

Method of Controlling O-Linked Glycosylation of Antibodies

#1660

20120058111

2012-03-08

Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them

#1661

20120045816

2012-02-23

Novel Glycosylated Polypeptides

#1662

20120039908

2012-02-16

Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions

#1663

20120039807

2012-02-16

Anti-tenascin-C A2 antibodies and methods of use

#1664

20120027754

2012-02-02

Treatment and Prevention of Chronic Asthma Using Antagonists of Integrin AlphavBeta6

#1665

20120014960

2012-01-19

Composition comprising antibodies to LINGO or fragments thereof

#1666

20120014955

2012-01-19

Methods of reducing CRP and/or increasing serum albumin in patients in need using IL-6 antibodies of defined epitopic specificity

#1667

20120011600

2012-01-12

Optimizing glycan processing in plants

#1668

20120010387

2012-01-12

Antibody variants composition

#1669

20120009189

2012-01-12

Antibody composition with altered Fab sialylation

#1670

20120003695

2012-01-05

METABOLIC ENGINEERING OF A GALACTOSE ASSIMILATION PATHWAY IN THE GLYCOENGINEERED YEAST PICHIA PASTORIS

#1671

20120003211

2012-01-05

Immunoglobulins with reduced aggregation

#1672

20110318340

2011-12-29

DEGLYCOSYLATED ANTIBODIES

#1673

20110313137

2011-12-22

HER2 ANTIBODY COMPOSITIONS

#1674

20110313136

2011-12-22

IgG-Fc FRAGMENT AND PROCESS FOR PRODUCING THE SAME

#1675

20110311999

2011-12-22

Diagnostic prediction of rheumatoid arthritis and systemic lupus erythematosus

#1676

20110311612

2011-12-22

Humanized neuraminidase antibody and methods of use thereof

#1677

20110305629

2011-12-15

Anti-αβantibodies and uses thereof

#1678

20110294984

2011-12-01

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

#1679

20110294150

2011-12-01

IMMUNOGLOBULIN GLYCOSYLATION PATTERN ANALYSIS

#1680

20110293622

2011-12-01

Nucleic acids encoding anti-IL-6 antibodies of defined epitopic specificity

#1681

20110293613

2011-12-01

Bispecific antibodies

#1682

20110293609

2011-12-01

Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity

#1683

20110293605

2011-12-01

ANTIBODY FORMULATION

#1684

20110287007

2011-11-24

Treatment and Prevention of Chronic Asthma Using Antagonists of Integrin AlphavBeta6

#1685

20110282037

2011-11-17

ANTIBODY PREPARATION

#1686

20110268746

2011-11-03

Human cytomegalovirus neutralizing antibodies and use thereof

#1687

20110263828

2011-10-27

Methods for modifying human antibodies by glycan engineering

#1688

20110262448

2011-10-27

Human antibodies that bind mesothelin, and uses thereof

#1689

20110262430

2011-10-27

NOVEL ANTIBODIES

#1690

20110256125

2011-10-20

Materials and methods for improved immunoglycoproteins

#1691

20110250643

2011-10-13

Antibody composition-producing cell

#1692

20110250201

2011-10-13

Antagonists of IL-6 to raise albumin and/or lower CRP

#1693

20110243966

2011-10-06

SINGLE CHAIN Fc (ScFc) REGIONS, BINDING POLYPEPTIDES COMPRISING SAME, AND METHODS RELATED THERETO

#1694

20110243934

2011-10-06

EPHA3 ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA

#1695

20110243931

2011-10-06

COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES

#1696

20110243929

2011-10-06

ANTI-ICOS ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE

#1697

20110236374

2011-09-29

GENETICALLY RECOMBINANT ANTIBODY COMPOSITION CAPABLE OF BINDING SPECIFICALLY TO GANGLIOSIDE GM2

#1698

20110229460

2011-09-22

ANTI-CD137 ANTIBODY AS AN AGENT IN THE TREATMENT OF INFLAMMATORY CONDITIONS

#1699

20110223658

2011-09-15

Monoclonal antibodies with enhanced ADCC function

#1700

20110223165

2011-09-15

Humanized C-kit antibody

#1701

20110217303

2011-09-08

Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever

#1702

20110209230

2011-08-25

Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1)

#1703

20110208673

2011-08-25

Antibodies to lymphotoxin-α

#1704

20110207171

2011-08-25

Oligosaccharide modification and labeling of proteins

#1705

20110200598

2011-08-18

COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR

#1706

20110200596

2011-08-18

MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS

#1707

20110200595

2011-08-18

TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR

#1708

20110200594

2011-08-18

Functionalized polypeptides

#1709

20110182904

2011-07-28

ANTIBODIES TO BONE MORPHOGENIC PROTEINS AND RECEPTORS THEREFOR AND METHODS FOR THEIR USE

#1710

20110171222

2011-07-14

Anti-HER3 antibodies and uses thereof

#1711

20110165659

2011-07-07

Biological products

#1712

20110165152

2011-07-07

COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE

#1713

20110165151

2011-07-07

COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE

#1714

20110162095

2011-06-30

Single-chain TNFSF fusion polypeptides

#1715

20110152504

2011-06-23

CD16A Binding Proteins and Use for the Treatment of Immune Disorders

#1716

20110151513

2011-06-23

SHRNA-MEDIATED INHIBITION OF EXPRESSION OF ALPHA-1,6-FUCOSYLTRANSFERASE

#1717

20110150867

2011-06-23

POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS

#1718

20110150865

2011-06-23

Antibodies to lymphotoxin-α

#1719

20110144308

2011-06-16

COMPOSITIONS AND METHODS FOR HUMANIZATION AND OPTIMIZATION OF N-GLYCANS IN PLANTS

#1720

20110142858

2011-06-16

Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation

#1721

20110142845

2011-06-16

NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE NOGO-66 RECEPTOR (NgR) AND USES THEREOF

#1722

20110142825

2011-06-16

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

#1723

20110135630

2011-06-09

CHEMICAL MODIFICATION OF ANTIBODY FRAGMENTS

#1724

20110124024

2011-05-26

Proteolysis Resistant Antibody Preparations

#1725

20110123549

2011-05-26

Antibodies to EphA3

#1726

20110117601

2011-05-19

Glycosylation Profile Analysis

#1727

20110117087

2011-05-19

METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN

#1728

20110111461

2011-05-12

Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof

#1729

20110098450

2011-04-28

Antibody molecules that bind to IL-6 receptor

#1730

20110097344

2011-04-28

Compositions, Methods for Treatment, and Diagnoses of Autoimmunity-Related Disorders and Methods for Making Such Compositions

#1731

20110097336

2011-04-28

Methods for modulating mannose content of recombinant proteins

#1732

20110091468

2011-04-21

Connective tissue growth factor antibodies

#1733

20110086050

2011-04-14

GLYCOPROTEIN COMPOSITIONS

#1734

20110081345

2011-04-07

SINGLE CHAIN FC, METHODS OF MAKING AND METHODS OF TREATMENT

#1735

20110076742

2011-03-31

Polynucleotides encoding novel PCSK9 variants

#1736

20110076277

2011-03-31

Methods of identifying anti-inflammatory compounds

#1737

20110076270

2011-03-31

Therapeutic Binding Molecules

#1738

20110070226

2011-03-24

Methods for treating or inhibiting thromboembolic disorders or for inhibiting coagulation

#1739

20110059115

2011-03-10

Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody

#1740

20110059075

2011-03-10

Aglycosylated immunoglobulin mutants

#1741

20110059073

2011-03-10

Method for treating infectious disease using monoclonal antibodies

#1742

20110059072

2011-03-10

Method for treating cancer using monoclonal antibodies

#1743

20110053223

2011-03-03

CELL CULTURE METHODS TO MAKE ANTIBODIES WITH ENHANCED ADCC FUNCTION

#1744

20110052610

2011-03-03

Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation

#1745

20110052582

2011-03-03

Humanized anti-CDCP1 antibodies

#1746

20110052574

2011-03-03

METHOD OF INHIBITION OF LEUKEMIC STEM CELLS

#1747

20110052571

2011-03-03

Method for treating idiopathic thrombocytopenic purpura using monoclonal antibodies

#1748

20110044985

2011-02-24

Antibodies directed against amyloid-beta peptide and methods using same

#1749

20110040074

2011-02-17

Production methods

#1750

20110039729

2011-02-17

Glycosylated protein expression in prokaryotes

#1751

20110039300

2011-02-17

ANTIBODIES WITH ENHANCED ADCC FUNCTIONS

#1752

20110033452

2011-02-10

Anti-Glypican 3 Antibody Having Modified Sugar Chain

#1753

20110028696

2011-02-03

Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues

#1754

20110027276

2011-02-03

Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells

#1755

20110027271

2011-02-03

ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION

#1756

20110021755

2011-01-27

Optimized Fc Variants

#1757

20110020331

2011-01-27

Method of treating lewis Y-expressing tumors

#1758

20110008834

2011-01-13

Polynucleotides encoding antibodies directed against amyloid-beta peptide

#1759

20110008330

2011-01-13

Compositions and methods of tolerizing a primate to an antigen

#1760

20110003338

2011-01-06

ANTIBODIES WITH ENHANCED ADCC FUNCTION

#1761

20100330594

2010-12-30

Early detection of diabetes

#1762

20100330076

2010-12-30

Immunoglobulin Fc polypeptides

#1763

20100322927

2010-12-23

GLYCOSYLATED ANTIBODIES

#1764

20100317083

2010-12-16

Method of assessing glycosylation state or functional quality of an IgG containing sample

#1765

20100311954

2010-12-09

Optimized Proteins that Target Ep-CAM

#1766

20100310464

2010-12-09

Antibodies

#1767

20100304436

2010-12-02

Fucosylation-deficient cells

#1768

20100303826

2010-12-02

Use of ADCC-optimized antibodies for treating weak patients

#1769

20100303808

2010-12-02

HUMANIZED ANTI-CD20 ANTIBODIES AND METHODS OF USE

#1770

20100303806

2010-12-02

Avian derived antibodies

#1771

20100297134

2010-11-25

Humanised antibodies with anti-tumour activity

#1772

20100297114

2010-11-25

Anti-CD40 targeted fusion proteins

#1773

20100291082

2010-11-18

Fusion protein with HIV antigen

#1774

20100290993

2010-11-18

Antibodies to IL-6 and use thereof

#1775

20100285021

2010-11-11

Antibodies which bind factor VIII

#1776

20100279433

2010-11-04

Assay method for Alzheimer's disease

#1777

20100278808

2010-11-04

Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

#1778

20100272734

2010-10-28

Compositions and methods for increasing muscle growth

#1779

20100272723

2010-10-28

Optimized antibodies that target CD19

#1780

20100272715

2010-10-28

Antibodies which bind and inhibit blood factor VIII

#1781

20100266607

2010-10-21

Methods of using anti-TNF antibodies for treating radiation damage to the digestive tract

#1782

20100266586

2010-10-21

Antibodies which bind and inhibit blood factor VIII

#1783

20100261248

2010-10-14

Pharmaceutical composition comprising an immunoglobulin FC region as a carrier

#1784

20100260751

2010-10-14

Methods and Structural Conformations of Antibody Preparations with Increased Resistance to Proteases

#1785

20100256339

2010-10-07

Bispecific Anti ErbB3 / Anti cMet Antibodies

#1786

20100255013

2010-10-07

GLYCOPROTEIN COMPOSITIONS

#1787

20100255012

2010-10-07

RECOMBINANT FUCOSE MODIFIED MONOVALENT HALF-ANTIBODIES OBTAINED BY MOLECULAR ENGINEERING

#1788

20100254989

2010-10-07

Bispecific Anti ErbB1 / Anti c Met Antibodies

#1789

20100254988

2010-10-07

Bispecific Anti ErbB2 / Anti cMet Antibodies

#1790

20100254987

2010-10-07

Engineered proteins with high affinity for DOTA chelates

#1791

20100254982

2010-10-07

Cancer associated glucose transporter 8 variant

#1792

20100249382

2010-09-30

Modified FC molecules

#1793

20100247533

2010-09-30

TREATMENT WITH A HUMANIZED ANTI-EGFR IgG1 ANTIBODY AND IRINOTECAN

#1794

20100247484

2010-09-30

COMBINATION THERAPY OF AN AFUCOSYLATED ANTIBODY AND ONE OR MORE OF THE CYTOKINES GM CSF, M CSF AND/OR IL3

#1795

20100240872

2010-09-23

Anti-Muc 17 antibody

#1796

20100240871

2010-09-23

Galactose Alpha(1-3) Galactose Compositions

#1797

20100239633

2010-09-23

Immunoglobulin constant region FC receptor binding agents

#1798

20100226930

2010-09-09

Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3

#1799

20100226912

2010-09-09

RECOMBINANT PROTEIN PRODUCTION IN AVIAN EBx® CELLS

#1800

20100215651

2010-08-26

Humanized antibodies that bind to CD19 and their uses